Immunome, Inc. Common Stock (IMNM) Stock
Key stats
- Market cap
- $2.12B
- Price / Earnings ratio
- -8.0x
- EPS (TTM)
- -$3.09
- Volume
- Loading
- 52-week high
- $30.06
- 52-week low
- $14.64
Source: third-party data provider, as of October 23, 2026
Compare with IMNM
Recent news

Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
IMNM

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
IMNM

Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors
Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors
IMNM

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
IMNM
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 37.18
- MACD 12/26/9
- -1.69
- EMA 9 of MACD
- -1.77
- MACD histogram
- 0.09
- SMA 50
- $23.57
- Price below SMA 50
- EMA 50
- $21.65
- Price below EMA 50
- SMA 200
- $22.56
- Price below SMA 200
- EMA 200
- $22.01
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
IMNM

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
IMNM

Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors
Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors
IMNM

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
IMNM

Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference
IMNM

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update
Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update
IMNM

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
IMNM

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors
IMNM

What This Immunome Sale Means a Day Before a Big FDA Milestone
What This Immunome Sale Means a Day Before a Big FDA Milestone
IMNM

Immunome Stock Up 32% in a Month: Here's What You Should Know
Immunome Stock Up 32% in a Month: Here's What You Should Know
IMNM
News tone: automated (AI) classification of the article's content, not a price prediction.
About Immunome, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Clay B. Siegall Ph.D. | Chairman, President & CEO | 1961 |
| Mr. Max Rosett | Chief Financial Officer | 1990 |
| Dr. Robert J. Lechleider M.D. | Chief Medical Officer | 1961 |
| Dr. Philip Tsai | Chief Technical Officer | 1968 |
| Dr. Jack Higgins Ph.D. | Chief Scientific Officer | 1980 |
| Ms. Sandra G. Stoneman Esq., J.D. | Chief Legal Officer, General Counsel & Corporate Secretary | 1973 |
| Mr. Kinney Horn | Chief Business Officer | 1975 |
| Mr. Roee Shahar | Executive Vice President of Commercial | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of October 23, 2026
Technical indicators
- RSI 14
- 37.18
- MACD 12/26/9
- -1.69
- EMA 9 of MACD
- -1.77
- MACD histogram
- 0.09
- SMA 50
- $23.57
- Price below SMA 50
- EMA 50
- $21.65
- Price below EMA 50
- SMA 200
- $22.56
- Price below SMA 200
- EMA 200
- $22.01
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst views
6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $24.00
- Average
- $33.80
- High
- $40.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +20.6 | -14.9 | -27.4 | |||||||||
| 2022 | -36.0 | -27.1 | -9.8 | -35.1 | +1.3 | -11.3 | +14.7 | +53.1 | -22.1 | -9.0 | -1.6 | -50.7 |
| 2023 | +62.3 | -13.1 | +9.9 | +1.3 | +4.4 | +45.9 | -10.6 | -11.0 | +27.7 | +7.3 | -13.0 | +37.2 |
| 2024 | +50.5 | +47.1 | -3.0 | -36.4 | +1.7 | -17.1 | +26.3 | +0.7 | +4.1 | -15.2 | +16.9 | -24.6 |
| 2025 | +4.7 | -8.9 | -24.7 | +40.4 | -1.1 | +2.6 | +24.2 | -10.2 | +26.2 | +41.7 | +8.4 | +17.2 |
| 2026 | +18.3 | -16.4 | -1.5 | +2.2 | -4.0 | +2.0 | +5.9 | +19.1 | -20.5 | -12.6 |



